{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T20:15:40Z","timestamp":1793218540260,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Fundamental Research Program of Shanxi Province","award":["No. 202303021222348"],"award-info":[{"award-number":["No. 202303021222348"]}]},{"name":"Fundamental Research Program of Shanxi Province","award":["No. 202303021221212"],"award-info":[{"award-number":["No. 202303021221212"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 32571692"],"award-info":[{"award-number":["No. 32571692"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"STI2030-Major Projects","award":["2021ZD 0201801"],"award-info":[{"award-number":["2021ZD 0201801"]}]},{"name":"National Key Research and Development Program of China","award":["2023YFC3605400"],"award-info":[{"award-number":["2023YFC3605400"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-46671-y","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T12:07:02Z","timestamp":1775131622000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Small-molecule PCSK9 inhibition enhances BBB amyloid-\u03b2 clearance and suppresses microglial inflammation in Alzheimer\u2019s disease models"],"prefix":"10.1038","volume":"16","author":[{"given":"Jie","family":"Miao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"46671_CR1","doi-asserted-by":"publisher","unstructured":"Alzheimer\u2019s disease facts and figures. Alzheimers Dement 20, 3708\u20133821, (2024). https:\/\/doi.org\/10.1002\/alz.13809 (2024).","DOI":"10.1002\/alz.13809"},{"key":"46671_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00269-y","volume":"7","author":"DS Knopman","year":"2021","unstructured":"Knopman, D. S. et al. Alzheimer disease.. Nat. Rev. Dis. Primers 7, 33. https:\/\/doi.org\/10.1038\/s41572-021-00269-y (2021).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"46671_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10753-022-01721-1","volume":"46","author":"S Thakur","year":"2023","unstructured":"Thakur, S., Dhapola, R., Sarma, P., Medhi, B. & Reddy, D. H. Neuroinflammation in Alzheimer\u2019s disease: Current progress in molecular signaling and therapeutics.. Inflammation 46, 1\u201317. https:\/\/doi.org\/10.1007\/s10753-022-01721-1 (2023).","journal-title":"Inflammation"},{"key":"46671_CR4","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun, M. A. et al. Donanemab in early Alzheimer\u2019s disease.. N. Engl. J. Med. 384, 1691\u20131704. https:\/\/doi.org\/10.1056\/NEJMoa2100708 (2021).","journal-title":"N. Engl. J. Med."},{"key":"46671_CR5","doi-asserted-by":"publisher","first-page":"156064","DOI":"10.1016\/j.metabol.2024.156064","volume":"163","author":"A Ajoolabady","year":"2025","unstructured":"Ajoolabady, A. et al. PCSK9 in metabolism and diseases. Metabolism 163, 156064. https:\/\/doi.org\/10.1016\/j.metabol.2024.156064 (2025).","journal-title":"Metabolism"},{"key":"46671_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2025.107652","volume":"213","author":"S Pelucchi","year":"2025","unstructured":"Pelucchi, S. et al. Neuronal PCSK9 regulates cognitive performances via the modulation of ApoER2 synaptic localization.. Pharmacol. Res. 213, 107652. https:\/\/doi.org\/10.1016\/j.phrs.2025.107652 (2025).","journal-title":"Pharmacol. Res."},{"key":"46671_CR7","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/j.1471-4159.2006.03928.x","volume":"98","author":"S Poirier","year":"2006","unstructured":"Poirier, S. et al. Implication of the proprotein convertase NARC-1\/PCSK9 in the development of the nervous system.. J. Neurochem. 98, 838\u2013850. https:\/\/doi.org\/10.1111\/j.1471-4159.2006.03928.x (2006).","journal-title":"J. Neurochem."},{"key":"46671_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220254","volume":"14","author":"C Picard","year":"2019","unstructured":"Picard, C. et al. Proprotein convertase subtilisin\/kexin type 9 (PCSK9) in Alzheimer\u2019s disease: A genetic and proteomic multi-cohort study.. PLoS One 14, e0220254. https:\/\/doi.org\/10.1371\/journal.pone.0220254 (2019).","journal-title":"PLoS One"},{"key":"46671_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064145","volume":"8","author":"M Canuel","year":"2013","unstructured":"Canuel, M. et al. Proprotein convertase subtilisin\/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1).. PLoS One 8, e64145. https:\/\/doi.org\/10.1371\/journal.pone.0064145 (2013).","journal-title":"PLoS One"},{"key":"46671_CR10","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine, M. S. et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Engl. J. Med. 376, 1713\u20131722. https:\/\/doi.org\/10.1056\/NEJMoa1615664 (2017).","journal-title":"N. Engl. J. Med."},{"key":"46671_CR11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41582-020-00435-y","volume":"17","author":"F Leng","year":"2021","unstructured":"Leng, F. & Edison, P. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?. Nature Reviews Neurology 17, 157\u2013172. https:\/\/doi.org\/10.1038\/s41582-020-00435-y (2021).","journal-title":"Nature Reviews Neurology"},{"key":"46671_CR12","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1093\/cvr\/cvy079","volume":"114","author":"Z Ding","year":"2018","unstructured":"Ding, Z. et al. PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages. Cardiovasc. Res. 114, 1145\u20131153. https:\/\/doi.org\/10.1093\/cvr\/cvy079 (2018).","journal-title":"Cardiovasc. Res."},{"key":"46671_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9070793","author":"SS Sundararaman","year":"2021","unstructured":"Sundararaman, S. S., D\u00f6ring, Y. & van der Vorst, E. P. C. PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology. Biomedicines https:\/\/doi.org\/10.3390\/biomedicines9070793 (2021).","journal-title":"Biomedicines"},{"key":"46671_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-022-04237-x","volume":"79","author":"AD Mazura","year":"2022","unstructured":"Mazura, A. D. et al. PCSK9 acts as a key regulator of A\u03b2 clearance across the blood-brain barrier. Cell. Mol. Life Sci. 79, 212. https:\/\/doi.org\/10.1007\/s00018-022-04237-x (2022).","journal-title":"Cell. Mol. Life Sci."},{"key":"46671_CR15","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.drudis.2022.01.014","volume":"27","author":"S Ahamad","year":"2022","unstructured":"Ahamad, S., Mathew, S., Khan, W. A. & Mohanan, K. Development of small-molecule PCSK9 inhibitors for the treatment of hypercholesterolemia. Drug Discov. Today 27, 1332\u20131349. https:\/\/doi.org\/10.1016\/j.drudis.2022.01.014 (2022).","journal-title":"Drug Discov. Today"},{"key":"46671_CR16","doi-asserted-by":"publisher","first-page":"15513","DOI":"10.1021\/acs.jmedchem.2c01290","volume":"65","author":"S Ahamad","year":"2022","unstructured":"Ahamad, S. & Bhat, S. A. Recent update on the development of PCSK9 inhibitors for hypercholesterolemia treatment. J. Med. Chem. 65, 15513\u201315539. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c01290 (2022).","journal-title":"J. Med. Chem."},{"key":"46671_CR17","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ejmech.2018.11.011","volume":"162","author":"S Xu","year":"2019","unstructured":"Xu, S., Luo, S., Zhu, Z. & Xu, J. Small molecules as inhibitors of PCSK9: Current status and future challenges. Eur. J. Med. Chem. 162, 212\u2013233. https:\/\/doi.org\/10.1016\/j.ejmech.2018.11.011 (2019).","journal-title":"Eur. J. Med. Chem."},{"key":"46671_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2025.117031","volume":"239","author":"P Jin","year":"2025","unstructured":"Jin, P. et al. PCSK9 inhibition mitigates vulnerable plaque formation induced by hyperhomocysteinemia through regulating lipid metabolism and inflammation. Biochem. Pharmacol. 239, 117031. https:\/\/doi.org\/10.1016\/j.bcp.2025.117031 (2025).","journal-title":"Biochem. Pharmacol."},{"key":"46671_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043428","author":"E Paduraru","year":"2023","unstructured":"Paduraru, E. et al. Zebrafish as a Potential Model for Neurodegenerative Diseases: A Focus on Toxic Metals Implications. Int J Mol Sci https:\/\/doi.org\/10.3390\/ijms24043428 (2023).","journal-title":"Int J Mol Sci"},{"key":"46671_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci15080849","author":"M Hayat","year":"2025","unstructured":"Hayat, M., Khola, N. U. H. & Ahmed, T. A Systematic Review of Preclinical Studies Investigating the Effects of Pharmacological Agents on Learning and Memory in Prolonged Aluminum-Exposure-Induced Neurotoxicity. Brain Sciences https:\/\/doi.org\/10.3390\/brainsci15080849 (2025).","journal-title":"Brain Sciences"},{"key":"46671_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2022.901953","volume":"15","author":"C Sun","year":"2022","unstructured":"Sun, C. et al. Eucommia ulmoides olive male flower extracts ameliorate Alzheimer\u2019s disease-like pathology in zebrafish via regulating autophagy, acetylcholinesterase, and the dopamine transporter. Front. Mol. Neurosci. 15, 901953. https:\/\/doi.org\/10.3389\/fnmol.2022.901953 (2022).","journal-title":"Front. Mol. Neurosci."},{"key":"46671_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s12033-025-01392-x","author":"D Uvarajan","year":"2025","unstructured":"Uvarajan, D. et al. Neuroprotective effects of berberine chloride against the aluminium chloride-induced Alzheimer\u2019s disease in zebra fish larvae. Mol. Biotechnol. https:\/\/doi.org\/10.1007\/s12033-025-01392-x (2025).","journal-title":"Mol. Biotechnol."},{"key":"46671_CR23","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.3233\/jad-170543","volume":"62","author":"DA Butterfield","year":"2018","unstructured":"Butterfield, D. A. & Boyd-Kimball, D. Oxidative stress, amyloid-\u03b2 peptide, and altered key molecular pathways in the pathogenesis and progression of Alzheimer\u2019s disease. J. Alzheimers Dis. 62, 1345\u20131367. https:\/\/doi.org\/10.3233\/jad-170543 (2018).","journal-title":"J. Alzheimers Dis."},{"key":"46671_CR24","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1172\/jci81108","volume":"126","author":"SE Storck","year":"2016","unstructured":"Storck, S. E. et al. Endothelial LRP1 transports amyloid-\u03b2(1\u201342) across the blood-brain barrier. J. Clin. Invest. 126, 123\u2013136. https:\/\/doi.org\/10.1172\/jci81108 (2016).","journal-title":"J. Clin. Invest."},{"key":"46671_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02426-1","volume":"10","author":"J Chen","year":"2025","unstructured":"Chen, J. et al. Rapid amyloid-\u03b2 clearance and cognitive recovery through multivalent modulation of blood-brain barrier transport. Signal Transduct. Target. Ther. 10, 331. https:\/\/doi.org\/10.1038\/s41392-025-02426-1 (2025).","journal-title":"Signal Transduct. Target. Ther."},{"key":"46671_CR26","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/ni.2639","volume":"14","author":"FJ Sheedy","year":"2013","unstructured":"Sheedy, F. J. et al. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat. Immunol. 14, 812\u2013820. https:\/\/doi.org\/10.1038\/ni.2639 (2013).","journal-title":"Nat. Immunol."},{"key":"46671_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2020.135279","volume":"736","author":"Y Liu","year":"2020","unstructured":"Liu, Y. et al. Beta-amyloid activates NLRP3 inflammasome via TLR4 in mouse microglia. Neurosci. Lett. 736, 135279. https:\/\/doi.org\/10.1016\/j.neulet.2020.135279 (2020).","journal-title":"Neurosci. Lett."},{"key":"46671_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1161\/circulationaha.120.046290","volume":"143","author":"Z Qi","year":"2021","unstructured":"Qi, Z. et al. PCSK9 (Proprotein Convertase Subtilisin\/Kexin 9) enhances platelet activation, thrombosis, and myocardial infarct expansion by binding to platelet CD36. Circulation 143, 45\u201361. https:\/\/doi.org\/10.1161\/circulationaha.120.046290 (2021).","journal-title":"Circulation"},{"key":"46671_CR29","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.atherosclerosis.2017.04.023","volume":"262","author":"ZH Tang","year":"2017","unstructured":"Tang, Z. H. et al. New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4\/NF-\u03baB pathway. Atherosclerosis 262, 113\u2013122. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.04.023 (2017).","journal-title":"Atherosclerosis"},{"key":"46671_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23169114","author":"RI Ja\u00e9n","year":"2022","unstructured":"Ja\u00e9n, R. I. et al. Functional Crosstalk between PCSK9 Internalization and Pro-Inflammatory Activation in Human Macrophages: Role of Reactive Oxygen Species Release. Int J Mol Sci https:\/\/doi.org\/10.3390\/ijms23169114 (2022).","journal-title":"Int J Mol Sci"},{"issue":"6012","key":"46671_CR31","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1126\/science.1197623","volume":"330","author":"KG Mawuenyega","year":"2010","unstructured":"Mawuenyega, K. G. et al. Decreased clearance of CNS beta-amyloid in Alzheimer\u2019s disease. Science 3301774. https:\/\/doi.org\/10.1126\/science.1197623 (2010).","journal-title":"Science"},{"key":"46671_CR32","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.3233\/jad-170993","volume":"62","author":"H Courtemanche","year":"2018","unstructured":"Courtemanche, H. et al. PCSK9 concentrations in cerebrospinal fluid are not specifically increased in Alzheimer\u2019s disease. J. Alzheimers Dis. 62, 1519\u20131525. https:\/\/doi.org\/10.3233\/jad-170993 (2018).","journal-title":"J. Alzheimers Dis."},{"key":"46671_CR33","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.bbi.2023.11.008","volume":"115","author":"A Vilella","year":"2024","unstructured":"Vilella, A. et al. PCSK9 ablation attenuates A\u03b2 pathology, neuroinflammation and cognitive dysfunctions in 5XFAD mice. Brain Behav. Immun. 115, 517\u2013534. https:\/\/doi.org\/10.1016\/j.bbi.2023.11.008 (2024).","journal-title":"Brain Behav. Immun."},{"key":"46671_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111195","volume":"126","author":"Y Zheng","year":"2024","unstructured":"Zheng, Y., Zhu, T., Li, G., Xu, L. & Zhang, Y. PCSK9 inhibitor protects against ischemic cerebral injury by attenuating inflammation via the GPNMB\/CD44 pathway. Int. Immunopharmacol. 126, 111195. https:\/\/doi.org\/10.1016\/j.intimp.2023.111195 (2024).","journal-title":"Int. Immunopharmacol."},{"key":"46671_CR35","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.bbi.2024.04.022","volume":"119","author":"J Wagner","year":"2024","unstructured":"Wagner, J. et al. PCSK9 inhibition attenuates alcohol-associated neuronal oxidative stress and cellular injury. Brain Behav. Immun. 119, 494\u2013506. https:\/\/doi.org\/10.1016\/j.bbi.2024.04.022 (2024).","journal-title":"Brain Behav. Immun."},{"key":"46671_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.tice.2025.102739","volume":"93","author":"T Su","year":"2025","unstructured":"Su, T. & Si, Y. PCSK9 exacerbates sevoflurane-induced neuroinflammatory response and apoptosis by up-regulating cGAS-STING signal. Tissue Cell 93, 102739. https:\/\/doi.org\/10.1016\/j.tice.2025.102739 (2025).","journal-title":"Tissue Cell"},{"key":"46671_CR37","doi-asserted-by":"publisher","first-page":"176332","DOI":"10.1016\/j.ejphar.2024.176332","volume":"965","author":"APR Nadiga","year":"2024","unstructured":"Nadiga, A. P. R., Krishna, K. L. & Suman & A novel Zebrafish model of Alzheimer\u2019s disease by Aluminium chloride; involving nitro-oxidative stress, neuroinflammation and cholinergic pathway. Eur. J. Pharmacol. 965, 176332. https:\/\/doi.org\/10.1016\/j.ejphar.2024.176332 (2024).","journal-title":"Eur. J. Pharmacol."},{"key":"46671_CR38","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1093\/brain\/awy132","volume":"141","author":"H Hampel","year":"2018","unstructured":"Hampel, H. et al. The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease. Brain 141, 1917\u20131933. https:\/\/doi.org\/10.1093\/brain\/awy132 (2018).","journal-title":"Brain"},{"key":"46671_CR39","doi-asserted-by":"publisher","DOI":"10.1111\/ejn.16586","volume":"61","author":"L Gence","year":"2025","unstructured":"Gence, L. et al. Gene expression patterns of the LDL receptor and its inhibitor Pcsk9 in the adult zebrafish brain suggest a possible role in neurogenesis. Eur. J. Neurosci. 61, e16586. https:\/\/doi.org\/10.1111\/ejn.16586 (2025).","journal-title":"Eur. J. Neurosci."},{"key":"46671_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2023.100426","volume":"64","author":"AK Jaafar","year":"2023","unstructured":"Jaafar, A. K., Techer, R., Chemello, K., Lambert, G. & Bourane, S. PCSK9 and the nervous system: A no-brainer?. J. Lipid Res. 64, 100426. https:\/\/doi.org\/10.1016\/j.jlr.2023.100426 (2023).","journal-title":"J. Lipid Res."},{"key":"46671_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00525","volume":"8","author":"M Labusch","year":"2020","unstructured":"Labusch, M., Mancini, L., Morizet, D. & Bally-Cuif, L. Conserved and divergent features of adult neurogenesis in zebrafish. Front. Cell Dev. Biol. 8, 525. https:\/\/doi.org\/10.3389\/fcell.2020.00525 (2020).","journal-title":"Front. Cell Dev. Biol."},{"key":"46671_CR42","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/jcph.840","volume":"57","author":"JP Gibbs","year":"2017","unstructured":"Gibbs, J. P. et al. Impact of target-mediated elimination on the dose and regimen of evolocumab, a human monoclonal antibody against proprotein convertase subtilisin\/kexin type 9 (PCSK9). J. Clin. Pharmacol. 57, 616\u2013626. https:\/\/doi.org\/10.1002\/jcph.840 (2017).","journal-title":"J. Clin. Pharmacol."},{"key":"46671_CR43","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa1701131","volume":"377","author":"RP Giugliano","year":"2017","unstructured":"Giugliano, R. P. et al. Cognitive function in a randomized trial of evolocumab. N. Engl. J. Med. 377, 633\u2013643. https:\/\/doi.org\/10.1056\/NEJMoa1701131 (2017).","journal-title":"N. Engl. J. Med."},{"key":"46671_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/life15121851","volume":"15","author":"V Suswidiantoro","year":"2025","unstructured":"Suswidiantoro, V. et al. The roles of PCSK9 in Alzheimer\u2019s disease: A systematic review of clinical, genetic, and preclinical evidence. Life 15, 1851 (2025).","journal-title":"Life"},{"key":"46671_CR45","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrneurol.2015.119","volume":"11","author":"JM Tarasoff-Conway","year":"2015","unstructured":"Tarasoff-Conway, J. M. et al. Clearance systems in the brain-implications for Alzheimer disease. Nat. Rev. Neurol. 11, 457\u2013470. https:\/\/doi.org\/10.1038\/nrneurol.2015.119 (2015).","journal-title":"Nat. Rev. Neurol."},{"key":"46671_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2019.00120","volume":"11","author":"MP Adorni","year":"2019","unstructured":"Adorni, M. P., Ruscica, M., Ferri, N., Bernini, F. & Zimetti, F. Proprotein convertase subtilisin\/kexin type 9, brain cholesterol homeostasis and potential implication for Alzheimer\u2019s disease. Front. Aging Neurosci. 11, 120. https:\/\/doi.org\/10.3389\/fnagi.2019.00120 (2019).","journal-title":"Front. Aging Neurosci."},{"key":"46671_CR47","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/s0140-6736(20)30367-6","volume":"396","author":"G Livingston","year":"2020","unstructured":"Livingston, G. et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet 396, 413\u2013446. https:\/\/doi.org\/10.1016\/s0140-6736(20)30367-6 (2020).","journal-title":"Lancet"},{"key":"46671_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117401","volume":"288","author":"MK Hussain","year":"2025","unstructured":"Hussain, M. K. et al. Phytomolecules as Alzheimer\u2019s therapeutics: A comprehensive review. Eur. J. Med. Chem. 288, 117401. https:\/\/doi.org\/10.1016\/j.ejmech.2025.117401 (2025).","journal-title":"Eur. J. Med. Chem."},{"key":"46671_CR49","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/aja.1002030302","volume":"203","author":"CB Kimmel","year":"1995","unstructured":"Kimmel, C. B., Ballard, W. W., Kimmel, S. R., Ullmann, B. & Schilling, T. F. Stages of embryonic development of the zebrafish. Dev. Dyn. 203, 253\u2013310. https:\/\/doi.org\/10.1002\/aja.1002030302 (1995).","journal-title":"Dev. Dyn."},{"key":"46671_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/molecules30183686","author":"Y Wu","year":"2025","unstructured":"Wu, Y. et al. The Neuroprotective Effects of Cyanidin Derivatives on AlCl(3)-Induced Zebrafish Model of Alzheimer\u2019s Disease. Molecules https:\/\/doi.org\/10.3390\/molecules30183686 (2025).","journal-title":"Molecules"},{"key":"46671_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/2045-8118-10-33","volume":"10","author":"DE Eigenmann","year":"2013","unstructured":"Eigenmann, D. E. et al. Comparative study of four immortalized human brain capillary endothelial cell lines, hCMEC\/D3, hBMEC, TY10, and BB19, and optimization of culture conditions, for an in vitro blood-brain barrier model for drug permeability studies. Fluids Barriers CNS 10, 33. https:\/\/doi.org\/10.1186\/2045-8118-10-33 (2013).","journal-title":"Fluids Barriers CNS"},{"key":"46671_CR52","doi-asserted-by":"publisher","first-page":"6504","DOI":"10.1039\/d5lc00937e","volume":"25","author":"W Wang","year":"2025","unstructured":"Wang, W. et al. A microfluidic chip recapitulating the human neurovascular unit with a functional blood-brain barrier for modeling gut-brain interactions. Lab Chip 25, 6504\u20136516. https:\/\/doi.org\/10.1039\/d5lc00937e (2025).","journal-title":"Lab Chip"},{"key":"46671_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2022.105417","volume":"160","author":"X P","year":"2022","unstructured":"P, X. et al. The role of LRP1 in A\u03b2 efflux transport across the blood-brain barrier and cognitive dysfunction in diabetes mellitus. Neurochem. Int. 160, 105417. https:\/\/doi.org\/10.1016\/j.neuint.2022.105417 (2022).","journal-title":"Neurochem. Int."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46671-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46671-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46671-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T07:34:57Z","timestamp":1779348897000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46671-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["46671"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-46671-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"4 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15780"}}